Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study

The Lancet Neurology

Volumn 17, Issue 3, 2018, Pages 241-250

  Gordon, Brian A ^a,b,c,w   Blazey, Tyler M ^a,c,w   Su, Yi ^a   Hari Raj, Amrita ^a   Dincer, Aylin ^a   Flores, Shaney ^a   Christensen, Jon ^a   McDade, Eric ^b   Wang, Guoqiao ^b   Xiong, Chengjie ^b,c   Cairns, Nigel J ^b   Hassenstab, Jason ^b,c   Marcus, Daniel S ^a   Fagan, Anne M ^b   Jack, Clifford R ^d   Hornbeck, Russ C ^a   Paumier, Katrina L ^b   Ances, Beau M ^b   Berman, Sarah B ^e   Brickman, Adam M ^f,g   Cash, David M ^h,i   Chhatwal, Jasmeer P ^j   Correia, Stephen ^k   Förster, Stefan ^l,m   Fox, Nick C ^h   Graff Radford, Neill R ⁿ   la Fougère, Christian ^m,o   Levin, Johannes ^m,p   Masters, Colin L ^q   Rossor, Martin N ^h   Salloway, Stephen ^k   Saykin, Andrew J ^k,r   Schofield, Peter R ^s,t   Thompson, Paul M ^u   Weiner, Michael M ^v   Holtzman, David M ^b   Raichle, Marcus E ^a,b   Morris, John C ^b   Bateman, Randall J ^b   Benzinger, Tammie L S ^a,b   more..

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f New York Presbyterian Columbia University Medical Center   (United States)

^g Harvard Medical School ^*  (United States)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

^k BROWN UNIVERSITY   (United States)

^l TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^m GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

ⁿ MAYO CLINIC   (United States)

^o UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^p UNIVERSITY OF MUNICH   (Germany)

^q UNIVERSITY OF MELBOURNE   (Australia)

^r INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^s NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^t UNIVERSITY OF NEW SOUTH WALES   (Australia)

^u UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^v UNIVERSITY OF CALIFORNIA   (United States)

^w NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; FLUORODEOXYGLUCOSE F 18; GLUCOSE; PITTSBURGH COMPOUND B; PRESENILIN 1; PRESENILIN 2; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; ANILINE DERIVATIVE; PSEN1 PROTEIN, HUMAN; PSEN2 PROTEIN, HUMAN; THIAZOLE DERIVATIVE;

ADULT; ALZHEIMER DISEASE; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; GENE MUTATION; GLUCOSE METABOLISM; HUMAN; INFERIOR TEMPORAL CORTEX; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDIAL FRONTAL CORTEX; MIDDLE AGED; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRECUNEUS; PRIORITY JOURNAL; SUPERIOR TEMPORAL SULCUS; BRAIN; BRAIN MAPPING; DIAGNOSTIC IMAGING; FAMILY HEALTH; GENETICS; NONPARAMETRIC TEST;

ADULT; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANILINE COMPOUNDS; BRAIN; BRAIN MAPPING; FAMILY HEALTH; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PRESENILIN-1; PRESENILIN-2; STATISTICS, NONPARAMETRIC; THIAZOLES;

EID: 85041606646     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(18)30028-0     Document Type: Article

References (45)

1. Pike, KE, Savage, G, Villemagne, VL, et al. β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 130 (2007), 2837–2844.
2. Hardy, JA, Higgins, GA, Alzheimer's disease: the amyloid cascade hypothesis. Science 256 (1992), 184–185.
3. Jack, CR, Knopman, DS, Jagust, WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12 (2013), 207–216.
4. Moulder, KL, Snider, BJ, Mills, SL, et al. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimers Res Ther, 5, 2013, 48.
5. Ryman, DC, Acosta-Baena, N, Aisen, PS, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology 83 (2014), 253–260.
6. Bateman, RJ, Xiong, C, Benzinger, TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367 (2012), 795–804.
7. Benzinger, TLS, Blazey, T, Jack, CR, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci USA 110 (2013), E4502–E4509.
8. Fleisher, AS, Chen, K, Quiroz, YT, et al. Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. JAMA Neurol 72 (2015), 316–324.
9. Yau, W-YW, Tudorascu, DL, McDade, EM, et al. Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study. Lancet Neurol 14 (2015), 804–813.
10. Weston, PSJ, Nicholas, JM, Lehmann, M, et al. Presymptomatic cortical thinning in familial Alzheimer disease: A longitudinal MRI study. Neurology 87 (2016), 2050–2057.
11. Wang, F, Gordon, BA, Ryman, DC, et al. Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. Neurology 87 (2015), 2050–2057.
12. Sala-Llonch, R, Lladó A, Fortea, J, et al. Evolving brain structural changes in PSEN1 mutation carriers. Neurobiol Aging 36 (2015), 1261–1270.
13. Schott, JM, Fox, NC, Frost, C, et al. Assessing the onset of structural change in familial Alzheimer's disease. Ann Neurol 53 (2003), 181–188.
14. Fagan, AM, Xiong, C, Jasielec, MS, et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med, 6, 2014, 226ra30.
15. Knight, WD, Kim, LG, Douiri, A, Frost, C, Rossor, MN, Fox, NC, Acceleration of cortical thinning in familial Alzheimer's disease. Neurobiol Aging 32 (2011), 1765–1773.
16. Kinnunen, KM, Cash, DM, Poole, T, et al. Presymptomatic atrophy in autosomal dominant Alzheimer's disease: a serial MRI study. Alzheimers Dement 14 (2018), 45–53.
17. Thompson, WK, Hallmayer, J, O'Hara, R, Alzheimer's Disease Neuroimaging Initiative. Design considerations for characterizing psychiatric trajectories across the lifespan: application to effects of APOE-ɛ4 on cerebral cortical thickness in Alzheimer's disease. Am J Psychiatry 168 (2011), 894–903.
18. Xu, Z, Shen, X, Pan, W, et al. Longitudinal analysis is more powerful than cross-sectional analysis in detecting genetic association with neuroimaging phenotypes. PLoS One, 9, 2014, e102312.
19. Mills, SM, Mallmann, J, Santacruz, AM, et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol 169 (2013), 737–743.
20. Reiman, EM, Langbaum, JBS, Fleisher, AS, et al. Alzheimer's prevention initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 26:suppl 3 (2011), 321–329.
21. Sperling, RA, Rentz, DMM, Johnson, KA, et al. The A4 study: stopping AD before symptoms begin?. Sci Transl Med, 6, 2014, 228fs13.
22. Morris, JC, The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43 (1993), 2412–2414.
23. Jack, CCR, Bernstein, MA, Borowski, BBJ, et al. Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative. Alzheimers Dement 6 (2010), 212–220.
24. Fischl, B, FreeSurfer. Neuroimage 62 (2012), 774–781.
25. Fischl, B, Dale, AMM, Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci USA 97 (2000), 11050–11055.
26. Su, Y, D'Angelo, GM, Vlassenko, AG, et al. Quantitative Analysis of PiB-PET with FreeSurfer ROIs. PLoS One, 8, 2013, e73377.
27. Su, Y, Blazey, TM, Snyder, AZ, et al. Partial volume correction in quantitative amyloid imaging. Neuroimage 107 (2015), 55–64.
28. Rousset, OG, Ma, Y, Evans, AC, Correction for partial volume effects in PET: principle and validation. J Nucl Med 39 (1998), 904–911.
29. Joshi, A, Koeppe, RA, Fessler, JA, Reducing between scanner differences in multi-center PET studies. Neuroimage 46 (2009), 154–159.
30. Bernal-Rusiel, JL, Reuter, M, Greve, DN, Fischl, B, Sabuncu, MR, Spatiotemporal linear mixed effects modeling for the mass-univariate analysis of longitudinal neuroimage data. Neuroimage 81 (2013), 358–370.
31. Bernal-Rusiel, JL, Greve, DN, Reuter, M, Fischl, B, Sabuncu, MR, Statistical analysis of longitudinal neuroimage data with Linear Mixed Effects models. Neuroimage 66 (2013), 249–260.
32. Bilgel, M, Prince, JL, Wong, DF, Resnick, SM, Jedynak, BM, A multivariate nonlinear mixed effects model for longitudinal image analysis: Application to amyloid imaging. Neuroimage 134 (2016), 658–670.
33. Jack, CR, Wiste, HJ, Lesnick, TG, et al. Brain β-amyloid load approaches a plateau. Neurology 80 (2013), 890–896.
34. Jack, CR, Vemuri, P, Wiste, HJ, et al. Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch Neurol 69 (2012), 856–867.
35. Carpenter, B, Lee, D, Brubaker, MA, et al. Stan: a probabilistic programming language. J Stat Softw, 2017 published online Jan 11. DOI:10.18637/jss.v076.i01.
36. Gelman, A, Lee, D, Guo, J, Stan: a probabilistic programming language for bayesian inference and optimization. J Educ Behav Stat 40 (2015), 530–543.
37. Gordon, BA, Blazey, T, Benzinger, TL, Regional variability in Alzheimer's disease biomarkers. Future Neurol 9 (2014), 131–134.
38. La Joie, R, Perrotin, A, Barré L, et al. Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid (Aβ) load in Alzheimer's disease dementia. J Neurosci 32 (2012), 16265–16273.
39. Grothe, MJ, Teipel, SJ, Spatial patterns of atrophy, hypometabolism, and amyloid deposition in Alzheimer's disease correspond to dissociable functional brain networks. Hum Brain Mapp 37 (2016), 35–53.
40. Edison, P, Archer, HA, Hinz, R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 68 (2007), 501–508.
41. Lehmann, M, Ghosh, PM, Madison, C, et al. Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. Brain 136 (2013), 844–858.
42. Förster, S, Grimmer, T, Miederer, I, et al. Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay. Biol Psychiatry 71 (2012), 792–797.
43. Alexopoulos, P, Kriett, L, Haller, B, et al. Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease. Alzheimers Dement 10 (2014), 684–689.
44. Förster, S, Yousefi, BH, Wester, H-J, et al. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease. Eur J Nucl Med Mol Imaging 39 (2012), 1927–1936.
45. Donohue, MC, Jacqmin-Gadda, H, Le Goff, M, et al. Estimating long-term multivariate progression from short-term data. Alzheimers Dement 10 (2014), S400–S410.